A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

被引：14

作者：

Kulasekararaj, Austin ^{[1
,2
]}

Risitano, Antonio M. ^{[3
]}

Maciejewski, Jaroslaw P. ^{[4
]}

Notaro, Rosario ^{[5
,6
]}

Browett, Peter ^{[7
]}

Lee, Jong-Wook ^{[8
]}

Huang, Mingjun ^{[9
]}

Geffner, Michael ^{[10
]}

Brodsky, Robert A. ^{[11
]}

机构：

[1] Kings Coll Hosp London, Dept Haematol, London, England

[2] Kings Collge London, London, England

[3] Univ Naples Federico II, Naples, Italy

[4] Cleveland Clin Fdn, Dept Translat Hematol & Oncol Res, Taussig Canc Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA

[5] Azienda Osped Univ Careggi, Florence, Italy

[6] Inst Studio Prevenz & Rete Oncol, Florence, Italy

[7] Univ Auckland, Dept Mol Med & Pathol, Sch Med, Auckland, New Zealand

[8] Catholic Univ Korea, Dept Hematol, Seoul St Marys Hosp, Seoul, South Korea

[9] Achillion Pharmaceut Inc, New Haven, CT USA

[10] Achillion Pharmaceut Inc, Blue Bell, PA USA

[11] Johns Hopkins Univ, Dept Med, Div Hematol, Baltimore, MD USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-124748

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3514

引用

页数：5

共 50 条

[21] Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study
Patriquin, Christopher J.
Bogdanovic, Andrija
Griffin, Morag
Kelly, Richard J.
Maciejewski, Jaroslaw P.
Mulherin, Brian
de Latour, Regis Peffault
Roeth, Alexander
Selvaratnam, Veena
Szer, Jeffrey
Al-Adhami, Mohammed
Horneff, Regina
Tan, Lisa
Yeh, Michael
Panse, Jens
ADVANCES IN THERAPY, 2024, 41 (05) : 2050 - 2069
[22] Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 2 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Not Previously Treated with Complement Inhibitors
Kulasekararaj, Austin
He, Guangsheng
Munir, Talha
Pu, Jeffrey
Risitano, Antonio
Roth, Alexander
Sima, Camelia S.
Appius, Anita
Sostelly, Alexandre
Sreckovic, Sasha
Vignal, Charlotte
Nishimura, Jun-Ichi
BLOOD, 2020, 136
[23] Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria
Hubert Schrezenmeier
Austin Kulasekararaj
Lindsay Mitchell
Régis Peffault de Latour
Timothy Devos
Shinichiro Okamoto
Richard Wells
Evan Popoff
Antoinette Cheung
Alice Wang
Ioannis Tomazos
Yogesh Patel
Jong Wook Lee
Annals of Hematology, 2024, 103 : 5 - 15
[24] Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria
Schrezenmeier, Hubert
Kulasekararaj, Austin
Mitchell, Lindsay
de Latour, Regis Peffault
Devos, Timothy
Okamoto, Shinichiro
Wells, Richard
Popoff, Evan
Cheung, Antoinette
Wang, Alice
Tomazos, Ioannis
Patel, Yogesh
Lee, Jong Wook
ANNALS OF HEMATOLOGY, 2024, 103 (01) : 5 - 15
[25] Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomised, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal haemoglobinuria (PNH)
Schrezenmeier, Hubert
Kulasekararaj, Austin
Mitchell, Lindsay
de latour, Regis Peffault
Devos, Timothy
Okamoto, Shinichiro
Wells, Richard
Popoff, Evan
Cheung, Antoinette
Johnston, Karissa
Wang, Jimmy
Gustovic, Philippe
Wang, Alice
Tomazos, Ioannis
Patel, Yogesh
Lee, Jong Wook
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 136 - 137
[26] Psychometric Evaluation of the PNH Symptom Questionnaire (PNH-SQ) Among Patients with Paroxysmal Nocturnal Hemoglobinuria from Three Phase 2 Clinical Trials with Pozelimab Monotherapy or in Combination with Cemdisiran
Hartford, Chris
Eusebi, Paolo
Kelly, Richard J.
Alin, Thibaud
Yang, Xinyu
Regnault, Antoine
Delevry, Dimittri
Lum, Ching
Rofail, Diana
BLOOD, 2023, 142
[27] Safety of Crovalimab Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Pooled Results from the Phase III COMMODORE 1, COMMODORE 2, and COMMODORE 3 Studies
Roeth, Alexander
Fu, Rong
He, Guangsheng
Alzahrani, Hazza A.
Chou, Sheng-Chieh
Hicheri, Yosr
Kazmierczak, Maciej
Recova, Viviane Lacorte
Uchiyama, Michihiro
Vladareanu, Ana Maria
Beveridge, Leigh
Buatois, Simon
Buri, Muriel
Shi, Dayu
Balachandran, Nadiesh
Srekovic, Sasha
Scheinberg, Phillip
BLOOD, 2023, 142
[28] Ravulizumab reduces the risk of thrombosis in adult patients with paroxysmal nocturnal hemoglobinuria and high disease activity: 2-year data from a Phase 3, open-label study
Roeth, A.
de latour, Peffault R.
Hill, A.
Fuereder, W.
Piatek, C.
Griffin, M.
Ogawa, M.
Wang, J.
Usuki, K.
Lee, J. W.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 165 - 165
[29] Vemircopan (ALXN2050) monotherapy in paroxysmal nocturnal haemoglobinuria: Interim data from phase 2 Open-Label Proof-of-Concept study
Browett, P.
Kulasekararaj, Austin
Notaro, R.
Ogawa, M.
Risitano, A.
Yu, J.
Lee, J. W.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 38 - 38
[30] Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 1 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Complement Inhibitors
Risitano, Antonio
Roth, Alexander
Kulasekararaj, Austin
Pu, Jeffrey
Nishimura, Jun-Ichi
Wright, Lilyan
Appius, Anita
Sostelly, Alexandre
Sreckovic, Sasha
Vignal, Charlotte
Munir, Talha
BLOOD, 2020, 136

← 1 2 3 4 5 →